CVS Health is reportedly closing down a number of its pharmacies installed in Target stores in the United States. The pharmacies are expected to be removed from the discount department store chain’s locations in early 2024.
As per CNN Business, the spokesperson of CVS Health confirmed the closure of its drug stores on Thursday, Jan. 11. It was said that the decision to stop its operations inside the Target outlets comes as retail pharmacy companies in the U.S. are faced with growing difficulties with their workforce, prescriptions business, and other aspects.
Schedule of the Pharmacy Shut Downs
The American retail pharmacy brand said it will close its stores in Target locations from next month until April this year. The company also said this is part of its strategy to spread out its stores and pharmacies even more. This information was shared with CNN through an email from CVS Pharmacy’s spokesperson, Amy Thibault.
The closing of the pharmacies is “based on our evaluation of changes in population, consumer buying patterns and future health needs to ensure we have the right pharmacy format in the right locations for patients,” the spokeswoman said.
Select Locations are Affected
Forbes reported that only select locations of Target stores are losing their CVS Health outlets this year. Then again, the company did not mention specific locations for the shutdown. The company is currently operating around 9,000 stores across the country.
“The pharmacy closures will begin in February and be completed by the end of April and impacted employees will be offered comparable roles within the company,” CVS Health said in a statement. “The closures are part of our plan to realign our national retail footprint and reduce store and pharmacy density and are based on our evaluation of changes in population, consumer buying patterns and future health needs to ensure we have the right pharmacy format in the right locations for patients.”
Photo by: Marques Thomas/Unsplash


AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
FDA Approves Mitapivat for Anemia in Thalassemia Patients
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 



